Abbott Labs (ABT) Tops Q3 EPS by 3c; Raises FY14 EPS Midpoint
Get Alerts ABT Hot Sheet
Price: $112.44 -2.64%
EPS Growth %: -6.8%
Financial Fact:
Selling, general and administrative: 1.63B
Today's EPS Names:
BFRI, HCTI, IMPM, More
EPS Growth %: -6.8%
Financial Fact:
Selling, general and administrative: 1.63B
Today's EPS Names:
BFRI, HCTI, IMPM, More
Join SI Premium – FREE
Abbott Labs (NYSE: ABT) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.62 billion.
- Worldwide sales of $5.6 billion from both continuing and discontinued operations increased 5.6 percent on an operational basis and 4.7 percent on a reported basis in the third quarter.
- In September, Abbott completed its acquisition of CFR Pharmaceuticals, more than doubling Abbott's branded generics pharmaceuticals presence in Latin America.
- In its Medical Devices business, Abbott received European approval for its revolutionary FreeStyle® Libre Flash Glucose Monitoring System that eliminates routine finger pricks and finger-prick calibration. Abbott also announced positive one-year results from the ABSORB II randomized clinical trial, demonstrating that the Absorb Bioresorbable Vascular Scaffold is comparable to XIENCE, Abbott's leading drug-eluting stent.
Abbott Labs sees FY2014 EPS of $2.25-$2.27, versus prior guidance of $2.19-$2.29 and the consensus of $2.24.
For earnings history and earnings-related data on Abbott Labs (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- Alpine Immune Sciences (ALPN) Reports FY Loss of $0.64
- Bit Digital (BTBT) Reports FY EPS of $0.12
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!